Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction

Mitić, Valentina; Stojanović, Dijana; Ilic, M; Stojanović, Miodrag; Petrovic, D.; Ignjatović, Aleksandra; Stefanović, Nikola; Kocić, Gordana; Bojanić, Vladmila

doi:10.1620/tjem.250.233

Cited by 18 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To measure galectin-3 concentration in circulation, three studies (6,7,15) used Abbot Laboratories' Architect System, one study (12) used a human galectin-3 assay kit , another (2) used a Quantikine USA kit, and the rest all used enzyme-linked immunosorbent assays (ELISAs) from various manufacturers. Detailed galectin-3 measurement information, including storage temperature and storage duration (where provided), is shown in Table 4.…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Baccouche¹,

Rhodenhiser

2023

Preprint

View full text Add to dashboard Cite

Introduction: HFpEF is one of the leading causes of death whose burden is estimated to expand in the coming decades. This paper examines the relationship between circulating levels of galectin 3, an emerging risk factor for cardiovascular disease, and the clinical diagnosis of HFpEF. Methods: The authors reviewed peer-reviewed literature and 18 studies met inclusion criteria. Study characteristics, study outcome definitions, assay characteristics, main findings, and measures of association were tabulated and summarized. Results: Five studies found significant associations between galectin 3 and HFpEF diagnosis compared to healthy controls, and one did not. Five studies found significant associations between galectin 3 concentration in circulation and severity of diastolic dysfunction. Three studies found a statistically significant association between circulating galectin 3 and all-cause mortality or rehospitalization. Two studies found levels of circulating galectin 3 to be a statistically significant predictor of later HFpEF onset. Finally, two studies examined whether galectin 3 was associated with incident HFpEF, one found a significant association and the other did not. Conclusion: Given the paucity of effective therapeutics for HFpEF, galectin 3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Baccouche¹,

Rhodenhiser

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The blockage of upregulated galectin-3 was found to decrease cardiovascular fibrosis and inflammation in a diet-induced obesity animal model [ 21 ]. In heart failure, systemic IL-33 R and galectin-3 were described as markers of left ventricular hypertrophy with reduced ejection fraction [ 22 , 23 ], as well as independent predictors for ischemia [ 24 ]. In the present study, galectin-3 showed no correlation with troponin T concentrations in polytrauma patients, but was significantly increased in the group of patients with troponin T levels ≥50 pg/mL compared to patients without a clinically relevant troponin T concentration.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors

Weber

Voth

Rottluff

et al. 2022

JCM

View full text Add to dashboard Cite

Polytrauma is one of the disorders with the greatest economic impact on healthcare in society and one predictor for poor outcome is cardiac damage. Interleukin 33 receptors (IL-33R) and galectin-3 are two new potential cardiac trauma biomarkers that are the subjects of this investigation. Additionally, this study assesses pre-existing cardiac damage or risk factors as predictors of cardiac damage after polytrauma. This retrospective study includes 107 polytraumatized patients with an ISS ≥16 admitted in a Level 1 Trauma Centre. Plasma samples were taken at admission. IL-33R and galectin-3 concentrations were detected in plasma samples by ELISA. Both did not correlate with the cardiac damage measured by troponin. Next to troponin, IL-33R was increased in patients with pre-existing cardiac comorbidities. In the subgroup of patients with cardiac comorbidities, the BMI and the initial blood sugar level were significantly increased compared to patients without cardiac comorbidities. Galectin-3 and IL-33R were shown to not correlate with cardiac damage. However, our data suggests that IL-33R protein should be revised in future studies as a marker of cardiac comorbidities. Further, our data indicate that patients with cardiac comorbidities represent a separate group of polytrauma patients characterized by higher concentrations of troponin, IL-33R, BMI and initial sugar level.

show abstract

“…Cardiac overload and myocardial cell injury can lead to reduced cardiac function, which results in compensatory changes such as ventricular hypertrophy and chamber enlargement, as well as corresponding changes in cardiomyocytes, extracellular matrix, and collagen fiber networks followed by ventricular remodeling, leading to further deterioration of cardiac function ( 18 ). Multiple factors are involved in the progression of HF, such as myocardial necrosis, apoptosis, autophagy, fibrosis, oxidative stress, inflammatory response, and neurohumoral regulatory disorders, as well as changing levels in a series of biomarkers ( 19 ). The American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) guidelines released in 2017 stated that BNP and NT-proBNP provide clear diagnostic value in patients with chronic HF ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis

Yang

Fan

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Objective: The diagnostic performance of soluble suppression of tumorigenicity (sST2) in heart failure (HF) had been investigated in multiple studies, but the results were inconsistent. This meta-analysis evaluated the diagnostic value of sST2 in HF.Methods: Pubmed, Web of Science, Embase, and Cochrane Library databases were searched until March 2021. Cohort studies or case-control studies relevant to the diagnostic value of sST2 in HF were screened, and true positive (TP), false positive (FP), false negative (FN), and true negative (TN) data were extracted for calculating sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC). The quality of the included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), the threshold effect was determined by calculating Spearman correlation coefficients and summary receiver operating characteristic (SROC) curve patterns, the heterogeneity was evaluated using the I2 statistic and the Galbraith radial plot, and sensitivity analysis was also performed. Deeks' test was used to assess publication bias.Results: A total of 11 studies from 10 articles were included in this meta-analysis. The Spearman correlation coefficient was 0.114, p = 0.739, and the SROC curve did not show a “shoulder-arm” shape, which suggests that there was no threshold effect, but study heterogeneity existed because of non-threshold effects. The combined sensitivity was 0.72 [95% confidence interval (CI): 0.65–0.78], specificity was 0.65 (95% CI: 0.45–0.81), PLR was 1.75 (95% CI: 1.33–2.31), NLR was 0.48 (95% CI: 0.37–0.63), DOR was 3.63 (95% CI: 2.29–5.74), and AUC was 0.75. The Deeks' test suggested no significant publication bias in the included studies (P = 0.94).Conclusion: sST has some diagnostic value in HF, but this should be further evaluated in additional studies with rigorous design and high homogeneity.

show abstract

Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction

Cited by 18 publications

References 26 publications

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors

The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis

Contact Info

Product

Resources

About